Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III MelanomaReinhard Dummer, Dirk Schadendorf, Marta Nyakas et al.|New England Journal of Medicine|2020Cited by 406
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III MelanomaGeorgina V. Long, Reinhard Dummer, Axel Hauschild et al.|New England Journal of Medicine|2024Cited by 123
Long-term benefit of adjuvant dabrafenib + trametinib (D+T) in patients (pts) with resected stage III <i>BRAF</i> V600–mutant melanoma: Five-year analysis of COMBI-AD.Axel Hauschild, Dirk Schadendorf, Reinhard Dummer et al.|Journal of Clinical Oncology|2020Cited by 23
1100P Restricted mean survival time (RMST) and cure-rate modeling in estimating survival benefit with adjuvant dabrafenib (D) plus trametinib (T) treatment in melanomaJohn M. Kirkwood, Mario Mandalà, Reinhard Dummer et al.|Annals of Oncology|2020Cited by 1